PMC:7546122 / 1409-1912 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T9","span":{"begin":49,"end":55},"obj":"Body_part"},{"id":"T10","span":{"begin":99,"end":107},"obj":"Body_part"},{"id":"T11","span":{"begin":379,"end":385},"obj":"Body_part"},{"id":"T12","span":{"begin":468,"end":474},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"d from it. An even higher number of convalescent plasma donors is needed to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the United States, for example, it took several years before the prevalence of WNV nAbs reached approximately 0.5% in the plasma donor community, at which point they became detectable in IVIG lots produced from plasma donated in the United States"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T7","span":{"begin":193,"end":203},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"d from it. An even higher number of convalescent plasma donors is needed to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the United States, for example, it took several years before the prevalence of WNV nAbs reached approximately 0.5% in the plasma donor community, at which point they became detectable in IVIG lots produced from plasma donated in the United States"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T13","span":{"begin":49,"end":55},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T14","span":{"begin":242,"end":247},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T15","span":{"begin":379,"end":385},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T16","span":{"begin":468,"end":474},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"d from it. An even higher number of convalescent plasma donors is needed to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the United States, for example, it took several years before the prevalence of WNV nAbs reached approximately 0.5% in the plasma donor community, at which point they became detectable in IVIG lots produced from plasma donated in the United States"}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":11,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"d from it. An even higher number of convalescent plasma donors is needed to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the United States, for example, it took several years before the prevalence of WNV nAbs reached approximately 0.5% in the plasma donor community, at which point they became detectable in IVIG lots produced from plasma donated in the United States"}

{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":232,"end":247},"obj":"Species"},{"id":"35","span":{"begin":249,"end":252},"obj":"Species"},{"id":"36","span":{"begin":336,"end":339},"obj":"Species"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"Tax:11082"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"Tax:11082"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"Tax:11082"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d from it. An even higher number of convalescent plasma donors is needed to result in neutralizing antibody (nAb) levels high enough for the resulting IVIG to afford protection against the new infectious agent. After the arrival of West Nile virus (WNV) in the United States, for example, it took several years before the prevalence of WNV nAbs reached approximately 0.5% in the plasma donor community, at which point they became detectable in IVIG lots produced from plasma donated in the United States"}